読み込み中
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
前日終値
$2.51
+$0.14 · +5.91%
時間外
$2.51
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
日中レンジ
現在 $2.51
52週レンジ
現在 $2.51
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
43
適正価値
センチメント
50
まちまち
リスク
70
高リスク
モメンタム
44
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
日中レンジ
現在 $2.51
52週レンジ
現在 $2.51
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 934.1万 USD | 725.11万 USD | 762.17万 USD | 632.47万 USD | 252.32万 USD |
| 販売・一般管理 | 1049.26万 USD | 811.47万 USD | 875.68万 USD | 858.62万 USD | 520.6万 USD |
| 営業費用 | 1983.35万 USD | 1536.58万 USD | 1637.85万 USD | 1491.09万 USD | 772.91万 USD |
| 受取利息 | — | — | — | 58.81万 USD | 1.77万 USD |
| 減価償却費と償却費 | — | 735 USD | 1284 USD | 1781 USD | 1403 USD |
| 営業利益 | −1983.35万 USD | −1536.58万 USD | −1637.85万 USD | −1491.09万 USD | −772.91万 USD |
| 純利益 | −2084.89万 USD | −1502.2万 USD | −1542.35万 USD | −1432.28万 USD | −771.14万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年6月27日 | 1:28 | — | — |
株式分割 | 2021年7月27日 | 1:4 | — | — |
株式分割 | 2020年10月30日 | 1:20 | — | — |
発効済み 2025年6月27日
1:28
発効済み 2021年7月27日
1:4
発効済み 2020年10月30日
1:20
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
